The Weekly Litigation News Digest is now live. Subscribe now

Methods And Compositions For Cns Delivery Of Iduronate-2-Sulfatase - EP3626258

The patent EP3626258 was granted to Shire Human Genetic Therapies on Aug 4, 2021. The application was originally filed on Jun 25, 2011 under application number EP19192679A. The patent is currently recorded with a legal status of "Revoked".

EP3626258

SHIRE HUMAN GENETIC THERAPIES
Application Number
EP19192679A
Filing Date
Jun 25, 2011
Status
Revoked
Sep 25, 2025
Publication Date
Aug 4, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GREEN CROSSMay 3, 2022HGFADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS6217552
DESCRIPTIONUS6534300
DESCRIPTIONUS6537785
OPPOSITIONEP3103469
OPPOSITIONUS2009130079
SEARCHUS2009017005
SEARCHWO2012023623

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents